BioLineRx (BLRX) Return on Sales (2024 - 2025)
BioLineRx (BLRX) recorded quarterly Return on Sales of 0.16% in Q4 2025, down 821.35% quarter-over-quarter from 0.02% in Q3 2025, and down 16.0% on a YoY basis from 0.19% in Q4 2024.
BioLineRx (BLRX) Return on Sales (2024 - 2025) Analysis & Trends
BioLineRx's Return on Sales history runs 2 years deep, the most recent figure standing at 0.16% for Q4 2025.
- In Q4 2025, Return on Sales fell 16.0% year-over-year to 0.16%; the TTM figure through Dec 2025 stood at 0.06% (down 5.0% YoY), while the FY2025 annual figure was 0.06%, down 6.0% from the prior year.
- Return on Sales was 0.16% for Q4 2025 at BioLineRx, down from 0.02% in the prior quarter.
- In the past five years, Return on Sales ranged from a high of 0.0% in Q4 2024 to a low of 0.16% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.00% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 0.00% |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 0.00% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | BioLineRx | 227.63 Mn | 211.90 Mn | 154,000.00 | -0.16% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -0.16% |
| Sep 30, 2025 | -0.02% |
| Jun 30, 2025 | -0.04% |
| Mar 31, 2025 | -0.07% |
| Dec 31, 2024 | 0.00% |
| Sep 30, 2024 | 0.00% |
| Jun 30, 2024 | 0.00% |
| Mar 31, 2024 | 0.00% |